A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Trial Details

NCT ID

NCT07221149

Phase

PHASE2 / PHASE3

Sponsor

Bristol-Myers Squibb

Status

RECRUITING

Cancer Type

Adenocarcinoma Esophageal Cancer

Interventions

• Pumitamig
• Folfox
• Capox
• Nivolumab

Locations (sample)

• Phoenix, Arizona, United States|33.44838,-112.07404
• Los Angeles, California, United States|34.05223,-118.24368
• Fort Myers, Florida, United States|26.62168,-81.84059
• St. Petersburg, Florida, United States|27.77086,-82.67927
• Atlanta, Georgia, United States|33.749,-84.38798

Key Eligibility Criteria

• Participants must be previously untreated with systemic treatment for advanced/metastatic disease, histologically or cytologically confirmed advanc…
• Participants must have a documented programmed cell death-(ligand)1 (PD-L1) ≥ 1 or \< 1 status for Phase 2, and document PD-L1 ≥ 1 status for the P…
• Participants must have documented human epidermal growth factor receptor 2 (HER2)-negative cancer, as determined according to local guidelines.
• Participants must have measurable disease as defined by RECIST v1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.